drugset / Trial / NCT01756716

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

NCT01756716 ↗

Phase 2 Completed 49 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR

Timeline

Start
2012-12
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-3995 Small molecule — —